SMARCA4 and cancer: Meanwhile, the P/LP variants of AXIN2, BMPR1A, MSH2 and SMARCA4 were identified in 5% (5/99) of the subjects in the non-cancer control group, including one 104-year-old woman (Table 2), which did not significantly differ from the rate in the cancer group, and therefore the significance of risk is uncertain.